Stock comparison
Masimo
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MASI
Masimo
Market cap
$9.35B
Sector
Healthcare
RMD
ResMed
Market cap
$29.57B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MASI | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 39D | 64C | RMD |
| Benjamin Graham | 66B | 67B | RMD |
| Philip Fisher |
Side-by-side metrics
| Metric | MASI | RMD |
|---|---|---|
| Market cap | $9.35B | $29.57B |
| P/E (TTM) | 122.1x | 19.6x |
| EV/EBIT | 31.0x | 17.1x |
| ROIC (TTM) | 18.28% | 19.63% |
| Gross margin | 61.73% | 61.69% |
| Net margin | 4.9% | 27.44% |
| Revenue CAGR 5y | 5.36% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MASI leads on
No clear edges - the other side wins or ties on every measured metric.
RMD leads on
- Dividend yield1.14%vs 0.0%+100%
- P/E (TTM)19.6xvs 122.1x+84%
- Net margin27.44%vs 4.9%+82%
More like RMD
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.